Vaishali Pharma

When is the next results date for Vaishali Pharma?

No Upcoming Board Meetings

What is the bonus history of the Vaishali Pharma?

Vaishali Pharma has a history of issuing bonus shares, with the most recent being a 1:1 bonus announced for October 15, 2024. Previously, a 3:5 bonus was issued on October 18, 2019.

Vaishali Pharma has a notable bonus history. The most recent bonus issue was announced as a 1:1 bonus, with an ex-date of October 15, 2024. Prior to that, the company issued a bonus in a 3:5 ratio, with the record date on October 18, 2019, and an ex-date of October 17, 2019. This indicates that Vaishali Pharma has actively engaged in rewarding its shareholders through bonus shares in the past.

Has Vaishali Pharma declared dividend?

No Dividend History Available

Is Vaishali Pharma overvalued or undervalued?

As of February 7, 2025, Vaishali Pharma is considered overvalued and risky, with a high PE ratio of 137.42, a PEG ratio of 9.89, and an EV to EBITDA ratio of 149.40, indicating unfavorable valuation metrics compared to its peers and a stock return of -7.57% versus the Sensex's 7.87%.

As of 7 February 2025, Vaishali Pharma's valuation grade has moved from very expensive to risky, indicating a shift in perception regarding its market position. The company is currently overvalued, as evidenced by its high PE ratio of 137.42 and a PEG ratio of 9.89, which suggests that the stock price is not justified by its earnings growth potential. Additionally, the EV to EBITDA ratio stands at 149.40, highlighting significant concerns about profitability relative to enterprise value.<BR><BR>In comparison to its peers, Vaishali Pharma's valuation metrics appear unfavorable; for instance, its PE ratio is significantly higher than the industry average, suggesting that investors are paying a premium for its shares. Notably, the company has underperformed relative to the Sensex over the past year, with a stock return of -7.57% compared to the Sensex's 7.87%. Given these factors, Vaishali Pharma is positioned as overvalued in the current market landscape.

What is the technical trend for Vaishali Pharma?

As of June 4, 2025, Vaishali Pharma's technical trend is mildly bearish, supported by moving averages and Bollinger Bands, despite a mildly bullish weekly MACD.

As of 4 June 2025, the technical trend for Vaishali Pharma has changed from bearish to mildly bearish. The weekly MACD indicates a mildly bullish stance, while the monthly MACD shows a mildly bearish trend. The Bollinger Bands and moving averages on the weekly and daily time frames are all signaling mildly bearish conditions. The KST is mildly bullish weekly but also mildly bearish monthly, and the Dow Theory reflects a mildly bearish stance on the weekly chart with no trend on the monthly. Overall, the current technical stance is mildly bearish, driven primarily by the moving averages and Bollinger Bands.

Who are the peers of the Vaishali Pharma?

Vaishali Pharma's peers include Mangalam Drugs, Zenith Drugs, Denis Chem Lab, Amwill Health, and others. In terms of management risk, Vaishali Pharma has below average risk, with a 1-year return of -17.84%, better than Mangalam Drugs but worse than Amwill Health.

Peers: The peers of Vaishali Pharma are Mangalam Drugs, Zenith Drugs, Denis Chem Lab, Amwill Health, Welcure Drugs, Parnax Lab, Smruthi Organic, Rajnish Wellness, Lactose (India), and Samrat Pharma.<BR><BR>Quality Snapshot: Excellent management risk is observed at Amwill Health and Smruthi Organic, while Good management risk is found at Zenith Drugs and Samrat Pharma. Average management risk is present at Mangalam Drugs, Denis Chem Lab, and Rajnish Wellness, while Below Average management risk is noted at Vaishali Pharma, Welcure Drugs, Parnax Lab, Lactose (India). Growth is Excellent at Rajnish Wellness, Good at Amwill Health and Parnax Lab, while Average growth is seen at Welcure Drugs, and Below Average growth is noted at Mangalam Drugs, Vaishali Pharma, Zenith Drugs, Denis Chem Lab, Smruthi Organic, and Lactose (India). Capital Structure is Excellent at Denis Chem Lab, Amwill Health, and Parnax Lab, Average at Zenith Drugs, while Below Average is observed at Mangalam Drugs, Vaishali Pharma, Welcure Drugs, Rajnish Wellness, Smruthi Organic, and Lactose (India).<BR><BR>Return Snapshot: The peer with the highest 1-year return is Amwill Health at 0.00%, while the peer with the lowest is Mangalam Drugs at -18.81%. Vaishali Pharma's 1-year return is -17.84%, which is better than Mangalam Drugs but worse than Amwill Health. Additionally, the six-month return is negative for Mangalam Drugs, Vaishali Pharma, Zenith Drugs, and Lactose (India).

Who are in the management team of Vaishali Pharma?

As of March 2022, the management team of Vaishali Pharma includes Atul Vasani (Chairman & Managing Director), Jagruti Vasani (Whole-time Director), Dewansh Vasani (Executive Director), and four independent directors: Ashvin Jamnadas Ganatra, Manish Bhagwandas Ved, Pratik Vikram Jakhelia, along with Vishwa Mekhia as Company Secretary & Compliance Officer.

As of March 2022, the management team of Vaishali Pharma includes the following individuals:<BR><BR>1. Atul Vasani - Chairman & Managing Director<BR>2. Jagruti Vasani - Whole-time Director<BR>3. Dewansh Vasani - Executive Director<BR>4. Ashvin Jamnadas Ganatra - Independent Director<BR>5. Manish Bhagwandas Ved - Independent Director<BR>6. Vishwa Mekhia - Company Secretary & Compliance Officer<BR>7. Pratik Vikram Jakhelia - Independent Director<BR><BR>As of March 2022, the management team consists of a mix of executive and independent directors, along with a compliance officer, reflecting a structured leadership approach within the company.

What does Vaishali Pharma do?

Vaishali Pharma Ltd, a Micro Cap company in the Pharmaceuticals & Biotechnology industry, was incorporated in 2008 and reported net sales of 322 Cr and a net loss of 43 Cr for the quarter ending March 2025. The company has a market cap of INR 134 Cr and key financial metrics include a P/E of 138.00 and a debt-equity ratio of 0.18.

Overview:<BR>Vaishali Pharma Ltd operates in the Pharmaceuticals & Biotechnology industry and is categorized as a Micro Cap company.<BR><BR>History:<BR>Vaishali Pharma Ltd was incorporated in 2008 as a Private Limited Company. It acquired the business of M/s. Vaishali Pharmachem from its promoter Mr. Atul Vasani on July 1, 2008. The latest quarterly results reported net sales and net profit for the period ending March 2025.<BR><BR>Financial Snapshot:<BR>Net Sales: 322 Cr (Quarterly Results - Mar 2025) <BR>Net Profit: -43 Cr (Quarterly Results - Mar 2025) <BR>Market Cap: INR 134 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>P/E: 138.00 <BR>Industry P/E: 37 <BR>Dividend Yield: 0.00% <BR>Debt Equity: 0.18 <BR>Return on Equity: 1.21% <BR>Price to Book: 1.98 <BR><BR>Contact Details:<BR>Address: 706 to 709 7th Floor Aravali, Business Centre Borivali(W) Mumbai Maharashtra : 400092 <BR>Tel: 91-22-28928833 <BR>Email: investor@vaishalipharma.com <BR>Website: http://www.vaishalipharma.com

Who are the top shareholders of the Vaishali Pharma?

The top shareholders of Vaishali Pharma include Atul Arvindbhai Vasani with 21.1%, and Sapan Anil Shah as the highest public shareholder at 6.82%. Individual investors own 65.24% of the company, with no pledged promoter holdings or mutual funds/foreign institutional investors involved.

The top shareholders of Vaishali Pharma include Atul Arvindbhai Vasani, who holds the largest stake at 21.1%. The highest public shareholder is Sapan Anil Shah, with a holding of 6.82%. Additionally, individual investors collectively own 65.24% of the company. Notably, there are no pledged promoter holdings, and the company does not have any mutual funds or foreign institutional investors holding shares.

How big is Vaishali Pharma?

As of 24th July, Vaishali Pharma Ltd has a market capitalization of 135.00 Cr, with recent net sales of 99.03 Cr and a net profit of 0.82 Cr. The balance sheet for March 2024 shows shareholder's funds of 42.84 Cr and total assets of 79.78 Cr.

As of 24th July, Vaishali Pharma Ltd has a market capitalization of 135.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, Vaishali Pharma reported Net Sales of 99.03 Cr and a Net Profit of 0.82 Cr.<BR><BR>The latest annual period for the balance sheet is March 2024, showing Shareholder's Funds of 42.84 Cr and Total Assets of 79.78 Cr.

How has been the historical performance of Vaishali Pharma?

Vaishali Pharma has experienced fluctuating financial performance, with net sales increasing from INR 52.31 crore in March 2021 to INR 99.03 crore in March 2025, but significant declines in profitability and negative cash flow in March 2025. Despite growth in total assets and a reduction in debt, the company's operating profit margin and profits before and after tax have sharply decreased.

Answer:<BR>The historical performance of Vaishali Pharma shows significant fluctuations in its financial metrics over the years.<BR><BR>Breakdown:<BR>Vaishali Pharma's net sales have shown a steady increase from INR 52.31 crore in March 2021 to INR 99.03 crore in March 2025, with a notable jump from INR 69.66 crore in March 2023 to INR 86.28 crore in March 2024. However, the total operating income peaked at INR 11.35 crore in March 2023 but dropped to INR 3.31 crore by March 2025. The operating profit margin, which was as high as 13.09% in March 2023, fell sharply to 0.1% in March 2025. Profit before tax also declined significantly from INR 8.85 crore in March 2023 to INR 1.23 crore in March 2025, while profit after tax decreased from INR 6.60 crore to INR 0.82 crore in the same period. The company's total assets increased from INR 66.08 crore in March 2020 to INR 109.66 crore in March 2025, reflecting growth in shareholder's funds, which rose to INR 64.92 crore. Despite this growth, total debt decreased from INR 14.72 crore in March 2020 to INR 8.50 crore in March 2025. Cash flow from operating activities has been negative in March 2025 at INR -18.00 crore, contrasting with positive cash flows in previous years. Overall, Vaishali Pharma's financial performance indicates a complex trajectory with growth in sales and assets but challenges in profitability and cash flow management.

Should I buy, sell or hold Vaishali Pharma Ltd?

Why is Vaishali Pharma Ltd falling/rising?

As of 08-May, Vaishali Pharma Ltd's stock price is slightly rising at 7.47, but it has significantly underperformed with a 38.01% decline over the past year and a concerning financial outlook, including negative EBITDA and low return on equity, indicating it may be a risky investment.

As of 08-May, Vaishali Pharma Ltd's stock price is experiencing a slight rise, currently at 7.47, with a change of 0.01 (0.13%) upwards. However, despite this minor increase, the stock has shown significant underperformance over various periods. For instance, in the last year, the stock has fallen by 38.01%, and over the past three years, it has decreased by 48.57%, consistently underperforming against the benchmark indices.<BR><BR>The company's financial health raises concerns, as indicated by a weak long-term fundamental strength with a -202.97% CAGR growth in operating profits over the last five years. Additionally, the company has recorded a negative EBITDA of Rs. -1.72 cr, and its profits have plummeted by 96% over the past year. The return on equity is low at an average of 8.79%, suggesting limited profitability per unit of shareholders' funds.<BR><BR>Moreover, the stock's performance today is described as inline with the sector, but it is trading below its 5-day, 100-day, and 200-day moving averages, indicating a lack of strong upward momentum. The broader market context also shows that the BSE Small Cap index has fallen by 13.31%, which could be influencing the stock's performance.<BR><BR>In summary, while there is a slight uptick in the stock price, the overall trend and financial indicators suggest that Vaishali Pharma Ltd is facing significant challenges, leading to a general perception of it being a risky investment.

Which are the latest news on Vaishali Pharma?